NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

INKT

MiNK Therapeutics Inc

Jul 14 • 04:00PM ET

40.61

Dollar change -23.56
Percentage change -36.71	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX ONC FATE ADAP IMTX PGEN AFMD CGEN KPTI TVRD

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.50	Insider Own	75.14%	Shs Outstand	3.97M	Perf Week	479.32%
Market Cap	161.86M	Forward P/E	-	EPS next Y	-1.84	Insider Trans	0.00%	Shs Float	0.99M	Perf Month	435.05%
Enterprise Value	163.75M	PEG	-	EPS next Q	-0.46	Inst Own	1.58%	Short Float	1.30%	Perf Quarter	435.75%
Income	-9.74M	P/S	-	EPS this Y	30.94%	Inst Trans	-21.92%	Short Ratio	0.02	Perf Half Y	420.64%
Sales	0.00M	P/B	-	EPS next Y	6.58%	ROA	-174.52%	Short Interest	0.01M	Perf YTD	482.72%
Book/sh	-5.50	P/C	50.11	EPS next 5Y	15.43%	ROE	-	52W High	76.00 -46.57%	Perf Year	366.78%
Cash/sh	0.81	P/FCF	-	EPS past 3/5Y	31.84% 16.86%	ROIC	-	52W Low	4.56 790.55%	Perf 3Y	188.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	69.71% 20.11%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	58.00%	Oper. Margin	-	ATR (14)	7.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	68.63	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.30	EPS Q/Q	36.60%	SMA20	242.62%	Beta	0.26	Target Price	35.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	345.12%	Rel Volume	6.35	Prev Close	64.17
Employees	23	LT Debt/Eq	-	Earnings	May 15 BMO	SMA200	398.48%	Avg Volume	792.02K	Price	40.61
IPO	Oct 15, 2021	Option/Short	No / No	EPS/Sales Surpr.	-15.19% -	Trades		Volume	5,026,291	Change	-36.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Downgrade	William Blair	Outperform → Mkt Perform

Jul-14-25 08:04AM	MiNK Therapeutics stock falls after William Blair downgrade (Investing.com) -36.71%
Jul-11-25 07:30AM	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer (GlobeNewswire) +730.14%
Jun-10-25 01:33PM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire) +5.84%
Jun-02-25 09:29AM	MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients (GlobeNewswire)
May-16-25 03:09AM	MiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +5.01%
11:48PM	Loading…
May-15-25 11:48PM	Q1 2025 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress (GlobeNewswire)
May-05-25 12:30PM	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report (GlobeNewswire)
Mar-19-25 03:01AM	MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-18-25 11:42PM	Q4 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress (GlobeNewswire)
Mar-04-25 07:30AM	MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (GlobeNewswire) -7.88%
Feb-24-25 08:30AM	MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) +5.45%
Feb-20-25 07:30AM	MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Feb-12-25 01:00PM	MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) -7.86%
02:13PM	Loading…
Jan-23-25 02:13PM	MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI (GlobeNewswire)
Dec-18-24 09:45AM	MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting (GlobeNewswire) -14.02%
Nov-15-24 02:17AM	Q3 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:00AM	MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update (GlobeNewswire) -5.59%
Nov-11-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report (GlobeNewswire)
Nov-07-24 10:00AM	MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 (GlobeNewswire)
Oct-31-24 09:15AM	MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors (GlobeNewswire)
Oct-09-24 06:15PM	MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 07:30AM	MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors (GlobeNewswire)
Oct-04-24 09:10AM	MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 (GlobeNewswire)
Sep-03-24 07:30AM	MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-13-24 07:00AM	MiNK Reports Second Quarter 2024 Results and Business Update (GlobeNewswire)
Aug-01-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report (GlobeNewswire)
Jul-31-24 07:30AM	MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
12:00PM	Loading…
Jul-11-24 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +11.36%
Jun-05-24 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-24 07:30AM	MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting (GlobeNewswire)
May-15-24 03:04AM	MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ... (GuruFocus.com) -7.14%
May-14-24 11:52AM	INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +14.31%
07:30AM	MiNK Reports First Quarter 2024 Results (GlobeNewswire)
May-13-24 07:30AM	MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer (GlobeNewswire) +8.87%
Apr-30-24 07:30AM	MiNK to Provide Corporate Update and First Quarter 2024 Financial Report (GlobeNewswire)
Apr-08-24 12:00PM	MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) -15.38%
Mar-25-24 12:00PM	All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy (Zacks) +5.47%
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:06PM	Q4 2023 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	MiNK Reports Fourth Quarter and Year-End 2023 Results (GlobeNewswire)
Mar-07-24 07:30AM	MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (GlobeNewswire)
Mar-06-24 08:30AM	MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire)
Feb-14-24 08:00AM	First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab (GlobeNewswire) +7.75%
Feb-06-24 08:00AM	MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications (GlobeNewswire) +10.25%
Jan-30-24 08:00AM	MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene (GlobeNewswire)
Dec-20-23 07:30AM	ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (GlobeNewswire)
Nov-09-23 08:05AM	MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges (GuruFocus.com) -6.72%
07:00AM	MiNK Therapeutics Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-03-23 12:00PM	MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire) +13.59%
Oct-30-23 08:00AM	MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update (GlobeNewswire) +7.62%
Sep-27-23 09:05AM	MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire)
Aug-24-23 08:30AM	MiNK Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -8.24%
Aug-10-23 07:30AM	MiNK Therapeutics Reports Second Quarter 2023 Results (GlobeNewswire) +6.67%
Jul-28-23 08:30AM	MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update (GlobeNewswire)
Jun-05-23 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-23 08:30AM	MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference (GlobeNewswire) +16.85%
May-18-23 08:30AM	MiNK's Novel FAP-CAR-iNKT Presented at ASGCT (GlobeNewswire)
May-11-23 08:00AM	MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results (GlobeNewswire) +7.28%
Apr-27-23 08:30AM	MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -8.29%
Apr-18-23 01:32PM	MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting (GlobeNewswire)
Apr-16-23 08:03AM	We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate (Simply Wall St.)
Apr-04-23 09:55AM	MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-30-23 08:41AM	Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics (Business Wire) -6.38%
Mar-29-23 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-24-23 07:36AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 08:00AM	MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-15-23 08:45AM	MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting (GlobeNewswire) -5.63%
Mar-07-23 09:00AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.35%
Feb-16-23 09:28AM	MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-11-23 02:25PM	MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference (GlobeNewswire)
Dec-22-22 10:49AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript (Insider Monkey)
Nov-17-22 09:00AM	MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference (GlobeNewswire) -5.90%
Nov-10-22 09:05AM	MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline (GlobeNewswire) -12.80%
Nov-06-22 09:39AM	Will MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely? (Simply Wall St.)
Nov-03-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results (GlobeNewswire) +5.63%
Oct-20-22 09:00AM	MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-05-22 09:16AM	MiNK Therapeutics to Host R&D Event November 10, 2022 (GlobeNewswire) +6.76%
08:30AM	MiNK Selected for Five Presentations at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Aug-31-22 09:00AM	MiNK Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.35%
Aug-16-22 06:16AM	Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)? (Simply Wall St.)
Aug-09-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 08:30AM	MiNK Therapeutics to Participate at BTIG Biotechnology Conference (GlobeNewswire)
Jul-27-22 08:30AM	MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update (GlobeNewswire) +6.06%
May-25-22 08:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-10-22 08:00AM	MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report (GlobeNewswire) -13.64%
May-09-22 08:43AM	Here's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Situation (Simply Wall St.) -9.74%
Apr-27-22 05:19PM	MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update (GlobeNewswire) +15.25% -12.84%
Mar-18-22 08:30AM	MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 04:35PM	MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update (GlobeNewswire)
09:28AM	MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers (GlobeNewswire)
Mar-01-22 08:00AM	Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report (GlobeNewswire)
Jan-15-22 07:47AM	Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jan-12-22 09:41AM	MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference (GlobeNewswire) +7.69%
Nov-17-21 04:15PM	MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.01% -5.83%
Nov-12-21 07:30PM	Agenus inc (AGEN) Q3 2021 Earnings Call Transcript (Motley Fool) -18.12% +6.28%
07:00AM	MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 (GlobeNewswire)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INKT

MiNK Therapeutics Inc

Upgrade your FINVIZ experience